A BRCA positive is a schedule, not a sentence

First thing: get the actual lab report as a PDF and put it somewhere you'll still be able to find it in nine years. Not the phone call. Not the portal summary that says "positive." The report, with the gene named, the variant written out in that ugly string of letters and numbers, and the testing lab's name at the top. You'll be handing that document to a surgeon, a counselor, and eventually to your sister, your brother, and your daughter's doctor. A screenshot of a text from your aunt won't cut it.

Then read it slowly, because "positive" gets used loosely and the difference matters.

Pathogenic, likely pathogenic, or a VUS

There are three results that people mistake for each other. A pathogenic or likely pathogenic variant is the real thing, and it's what the rest of this piece is about. A variant of uncertain significance isn't. A VUS means the lab found a spelling change nobody has enough data on yet. It's not a diagnosis, it's not a reason for surgery, and most VUS findings get reclassified to benign as the databases grow. If your report says VUS, your job is to ask a genetic counselor to re-query the lab in a couple of years, and then go live your life.

Check which gene, too. BRCA1 and BRCA2 don't behave identically, and a lot of modern panels test 30, 60, sometimes 80-plus genes at once. A PALB2 or CHEK2 result comes with its own management, not BRCA's. If the lab is a direct-to-consumer service, know its limits. Some consumer reports only look at three specific founder variants common in Ashkenazi Jewish families. A "negative" on that narrow a test rules out almost nothing, and a positive still needs confirming in a clinical lab.

Find a certified genetic counselor before you find an opinion. The National Society of Genetic Counselors runs a public directory at findageneticcounselor.nsgc.org, and many programs do telehealth, so rural doesn't mean out of luck.

The numbers, without the theater

Per the National Cancer Institute, roughly 13 percent of women in the general population develop breast cancer at some point. For women with a harmful BRCA1 variant, published estimates run in the range of 55 to 72 percent by age 70 to 80. BRCA2 lands somewhat lower, around 45 to 69 percent. Ovarian cancer is where the gap widens most sharply against a general-population risk of about 1 percent: roughly 39 to 44 percent with BRCA1, and about 11 to 17 percent with BRCA2.

Those are ranges, not verdicts. A real number for you depends on your gene, your variant, your family's pattern, and your age right now. That's a conversation with a counselor holding your pedigree, not a number you pull off a web page.

A BRCA result doesn't tell you that you'll get cancer. It tells you which doctors you're now on a first-name basis with.

The calendar does most of the work

High-risk breast surveillance, under the guidelines oncologists actually use, generally starts young: annual breast MRI with contrast around age 25, mammography added around 30, and the two often staggered so you're getting imaged roughly every six months. Clinical breast exams in between. That's it. That's the whole heavy lift. Two appointments a year, booked the same week you book the dentist.

Ovarian is the honest problem. There's no screening test that's been shown to catch it early enough to save lives. CA-125 blood tests and transvaginal ultrasound get offered, and plenty of women do them, but nobody should tell you they're reliable. Know that going in. It's the reason the surgical conversation for ovaries happens earlier and more firmly than the one for breasts.

Ask, at your first specialist visit, who owns your calendar. A high-risk clinic that tracks and recalls you is worth switching for. Left to a busy primary care office, the MRI quietly becomes a fourteen-month MRI, then an eighteen-month one.

Surgery, chemoprevention, and the timing question

Risk-reducing mastectomy cuts breast cancer risk dramatically, and for some women it's the right call in their thirties. For others, surveillance for a decade or two is a reasonable choice, and both can be defensible in the same family. Anybody who tells you there's one correct answer isn't accounting for your age, your kids, your pathology, or your willingness to sit in an MRI tube twice a year.

Removing the ovaries and fallopian tubes is the one where timing is tighter. Guidelines put it broadly between 35 and 40 for BRCA1 and 40 to 45 for BRCA2, after you're done having children. Say the trade-off out loud: that's surgical menopause, immediately, with real effects on bone density, cardiovascular risk, sleep, and how you feel day to day. Hormone therapy after the surgery is a legitimate discussion for many women, and it's one to have with a gynecologic oncologist who does this weekly, not with a message board.

There are also medication options, tamoxifen among them, that reduce breast cancer risk. And a note worth carrying: if cancer ever does show up, BRCA status changes treatment. PARP inhibitors exist because of this gene. Knowing puts you in a better position, not a worse one.

Do the insurance paperwork first

This is the part nobody warns you about. The Genetic Information Nondiscrimination Act of 2008 bars health insurers and most employers from using your genetic information against you. It does not cover life insurance, disability insurance, or long-term care insurance. Those markets can and do ask.

So if you're underinsured, price and lock those policies before the next round of family testing generates more paper. Then tell your relatives. Order matters here, and it costs you nothing but sequence.

Your daughters, and your sons

Each child of a carrier has a 50 percent chance of inheriting the variant. A coin flip, per kid, and the coin doesn't care that the last one came up clear. Your sons are in this too. BRCA2 in particular raises male breast cancer risk and is linked to prostate cancer, pancreatic cancer, and melanoma, and a son can pass it to his own daughters.

Testing children isn't the move. These are adult-onset risks, nothing changes before adulthood, and the decision belongs to her. Standard practice is to wait until 18 at the earliest, more often the early twenties, timed so results arrive before screening would start around 25.

What you owe a twelve-year-old is the truth in one sentence, delivered flat: "There's a gene in our family that makes some cancers more likely, I have it, there's a test for it, and when you're grown you can decide whether to take it." No tears, no vigil. Kids read your face, not your words.

To a twenty-two-year-old, hand over the PDF and the counselor's phone number. Then let go. If she waits three years, she waits three years. A daughter who feels managed will avoid the whole subject, which is the one outcome that actually hurts her.

Send one email to the cousins

Write a short, plain message: the gene, the variant as written on the report, the lab, and a line saying testing for a known family variant is usually cheap and fast. Send it to parents, siblings, aunts, uncles, and first cousins. Attach the PDF.

Some of them won't test. That's their call, and you're not the family's compliance officer. But nobody in your bloodline should learn about this gene from an oncologist in a hospital gown.

Book the MRI today. The rest of it keeps.

General education, not medical advice. Take your report to a certified genetic counselor and a high-risk clinic.